Business Context and Reporting Period
The filing identifies the registrant as Ambac Financial Group, Inc., not OCTAVE SPECIALTY GROUP INC. It is an unaudited Form 10-Q for the quarter and six months ended June 30, 2017. Ambac is a financial-services holding company providing financial guarantee insurance through Ambac Assurance Corporation and Ambac Assurance UK Limited. Its insurance operations are in runoff and have been unable to write new business since the deterioration of the insured portfolio after 2007.
Beginning in the second quarter of 2017, management reported Ambac as a single reportable segment following the substantial wind-down of its financial-services activities and changes in business management.
Key Financial Metrics
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| Net premiums earned | $43.2 million, versus $41.4 million | $90.8 million, versus $94.2 million |
| Net investment income | $85.2 million, versus $70.8 million | $166.7 million, versus $131.6 million |
| Total revenues | $172.8 million, versus $106.7 million | $299.1 million, versus $123.6 million |
| Losses and loss expenses | $66.1 million expense, versus $52.5 million benefit | $201.1 million expense, versus $157.8 million benefit |
| Net income attributable to common shareholders | $7.1 million, or $0.16 diluted EPS, versus $58.6 million, or $1.29 | $(118.3) million, or $(2.61) diluted EPS, versus $68.1 million, or $1.50 |
| Operating expenses | $31.1 million, versus $28.0 million | $59.0 million, versus $56.0 million |
| Interest expense | $28.2 million, versus $30.7 million | $59.8 million, versus $61.1 million |
Six-month operating cash flow was $(161.0) million, compared with $874.0 million provided in the prior-year period. Investing activities provided $295.5 million, while financing activities used $170.1 million. Cash and cash equivalents declined to $54.2 million from $91.0 million at December 31, 2016.
| Balance-sheet metric | June 30, 2017 | December 31, 2016 |
|---|---|---|
| Total assets | $23.005 billion | $22.636 billion |
| Total liabilities | $21.067 billion | $20.658 billion |
| Total stockholders’ equity | $1.938 billion | $1.978 billion |
| Long-term debt | $988.2 million, excluding VIE debt | $1.114 billion |
| Loss and loss expense reserves | $4.582 billion | $4.381 billion |
| Subrogation recoverable | $658.9 million | $684.7 million |
Total insured net par outstanding was $71.2 billion, down from $79.3 billion at year-end 2016. Below-investment-grade exposure was $15.2 billion, down from $16.8 billion. Puerto Rico exposure was approximately $2.1 billion and was classified as below investment grade.
Material Changes Versus the Prior Comparable Period
- Second-quarter net income declined primarily because prior-year results included a $52.5 million loss-and-loss-expense benefit, compared with a $66.1 million expense in 2017. The six-month comparison similarly shifted from a $157.8 million benefit to a $201.1 million expense.
- Loss development was driven largely by adverse developments in domestic public finance, particularly Puerto Rico, and interest accrued on Deferred Amounts. Domestic public-finance losses were $221.6 million for the six months.
- Net investment income increased by $14.4 million in the quarter and $35.1 million year to date, reflecting a larger portfolio and higher average returns.
- Interest-rate derivative results improved materially, producing gains of $34.1 million in the quarter and $32.6 million year to date, compared with losses of $36.3 million and $119.8 million, respectively, in the prior-year periods. The 2017 results included approximately $43.4 million of gain from the Augusta swap commutation.
- Operating expenses increased because of legal, consulting and advisory costs related to the proposed exit from rehabilitation, partly offset by lower compensation and reduced headcount.
- Derivative liabilities declined to $91.5 million from $319.3 million, primarily due to swap commutations and the treatment of variation margin as a reduction of derivative balances under new central-clearing rules.
- The last remaining investment agreement matured in March 2017, eliminating $82.4 million of related liabilities at June 30, 2017.
Guidance, Outlook, Risks and Unusual Items
Management provided no conventional earnings or revenue guidance. It emphasized active runoff, liability reduction, litigation recoveries, improved cost efficiency, capital-structure rationalization and selective transactions that could utilize tax attributes.
Management concluded that substantial doubt exists about Ambac’s ability to continue as a going concern because of uncertainty surrounding the Segregated Account rehabilitation and the Rehabilitator’s control over claims payments and Deferred Amount accretion. The financial statements nevertheless assume a going concern and contain no related adjustment.
On July 19, 2017, after the reporting period, Ambac and Ambac Assurance entered into a Rehabilitation Exit Support Agreement. The contemplated transactions would exchange certain surplus notes and satisfy Deferred Amounts using cash, new secured notes and certain existing surplus notes, with the objective of exiting the Segregated Account from rehabilitation. The estimated cash outflow was approximately $1.3 billion. Completion depends on court and regulatory approvals, exchange-offer participation of at least 85% of outstanding surplus-note principal, required consents, an IRS ruling and other conditions.
Ambac Assurance also entered into a commitment for $240 million of Tier 2 Notes secured by proceeds above $1.6 billion from specified RMBS litigation recoveries. Neither the rehabilitation exit transactions nor the Tier 2 Notes were assured of completion.
Puerto Rico remains the principal near-term risk. Title III proceedings were commenced for the Commonwealth, COFINA and PRHTA, and Ambac’s related litigation was largely stayed. Management estimated that adverse stress scenarios could increase public-finance loss reserves by approximately $1.6 billion, student-loan reserves by approximately $200 million and other-credit reserves by approximately $300 million. RMBS stress scenarios could increase reserves by approximately $80 million, or approximately $2 billion if estimated representation-and-warranty recoveries were entirely unavailable.
Ambac recorded approximately $1.884 billion of RMBS representation-and-warranty subrogation recoveries, net of reinsurance, but acknowledged substantial uncertainty regarding litigation outcomes, collectability, timing and regulatory intervention. The April 2017 Ballantyne litigation settlement produced a $144.6 million total benefit through reduced loss reserves, including an incremental $91.6 million recognized in the first quarter; it did not generate a direct cash payment to Ambac UK.
Ambac Assurance’s statutory policyholder surplus was $954.2 million at June 30, 2017, compared with $976.5 million at year-end 2016. Ambac UK reported a Solvency II capital-resources deficit of £15.0 million at March 31, 2017, versus a £67.1 million deficit at December 31, 2016, and remained deficient relative to regulatory capital requirements.
Most Important Facts for Investors to Verify
- Confirm the issuer identity: the supplied filing is for Ambac Financial Group, Inc., despite the request metadata naming OCTAVE SPECIALTY GROUP INC.
- Verify whether the Rehabilitation Exit Transactions received all required OCI, court, IRS and creditor approvals and whether the approximately $1.3 billion cash requirement was funded.
- Assess the outcome and timing of Puerto Rico Title III proceedings and related COFINA, PRHTA and PRIFA litigation.
- Reconcile the $3.923 billion net loss-reserve exposure with the disclosed stress-case reserve increases and evaluate the collectability of $1.884 billion of RMBS recoveries.
- Monitor Ambac Assurance’s statutory surplus, Ambac UK’s Solvency II deficit and restrictions on dividends or surplus-note payments.
- Evaluate liquidity after the $(161.0) million six-month operating cash outflow, the $54.2 million consolidated cash balance and potential rehabilitation-related cash needs.
- Separate recurring runoff economics from unusual items, including the Augusta swap gain, prior-year litigation recoveries, fair-value changes and derivative commutations.